drugset / Trial / NCT04482595
BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients
Phase 2
Unknown
50 enrolled
Humanetics Corporation
NYU Langone Health · collabNational Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate the safety and efficacy of BIO 300 Oral Suspension (BIO 300) as a therapy to improve lung function in patients that were hospitalized for severe COVID-19-related illness and continue to experience post-acute respiratory complications associated with Long-COVID after discharge. Patients will be randomized 1:1 to receive BIO 300 or placebo.
Timeline
- Start
- 2020-11-11
- Primary completion
- 2024-07-31
- Completion
- 2025-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Genistein | Other / unclassified | 1500 mg | Oral |